Skip to main content

Ordinary Share Class Portfolio

Ordinary Share Class Portfolio

Please click on the icons below to learn more about the portfolio of companies held by the Ordinary Shares (SENECA GROWTH CAPITAL VCT PLC ORD 1P).

+ Click for info

Arecor Ltd - Unquoted

- Click to close

Arecor Ltd - Unquoted


Arecor was a spin-out from Insense (qv) to commercialise technology developed by Insense for enabling biologics to maintain their integrity without the need for refrigeration – this both reduces cost and also helps deployment in developing countries where temperature monitored cold storage facilities are in short supply. The technology also assists in maintaining the integrity and function of proteins exposed to ionizing radiation as the means of sterilisation.

Visit the Arecor website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Jan 2008
cost: £141,000
valn at: 30/06/2018 £252,000
equity held: 1.9%

+ Click for info

Fuel 3D Technologies Ltd - Unquoted

- Click to close

Fuel 3D Technologies Ltd - Unquoted


Eykona was founded in 2007 to deploy computer vision technology (essentially 3D imaging) developed within Oxford University for developing a hand held camera to measure the volume of chronic wounds – this is a vital measurement for obtaining an understanding of whether a wound is getting better or worse, and hence assist determining the treatment to be applied.

The first production version of the camera was delivered in May 2010. The company is pursuing a recurring income business model.

The 3D imaging technology also has potential applications outside MedTech. One of the uses for which the camera was being used clinically in the US was to help create masks for dealing with patients suffering from facial burns – this resulted in becoming aware of the opportunity to develop the medical camera into an affordable handheld 3D scanner for use by both retail and business users within the 3D printing market – this product (with development partly funded via Kickstarter) is due to be launched in 2014. As part of this changed strategic direction, the Eykona business was restructured in 2014, resulting in the investment in Eykona Ltd becoming an investment in Fuel 3D Technologies Ltd.

Links:
Fuel 3D

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Mar 2010
cost: £299,000
valn at: 30/06/2018 £276,000
equity held: <1%

 

+ Click for info

Hallmarq Veterinary Imaging Ltd - Unquoted

- Click to close

Hallmarq Veterinary Imaging Ltd - Unquoted


Hallmarq is a Guildford-based company which specialises in developing low cost magnetic resonance imaging systems. The first application is for equine vets to enable the diagnosis of causes of lameness in horses that are not identifiable by any other method. Hallmarq has installed more than 70 units at leading equine veterinary practices and research centres around the world, and >37,000 scans have been carried out on horses using equipment supplied by Hallmarq. The next major development project is an MRI scanner for companion animals, a market which is significantly larger than the equine market – it was launched in 2013.

Visit the company website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Aug 2005
cost: £1,116,000
valn at: 30/06/2018 £2,029,000
equity held: 10.2%

+ Click for info

Immunobiology Ltd - Unquoted

- Click to close

Immunobiology Ltd - Unquoted


ImmunoBiology is a biotechnology company that is focused on developing products that could have applications in the treatment of a range of infectious diseases such as meningitis, tuberculosis, influenza and hepatitis C. The company’s technology is based on a the discovery that a group of proteins known as “heat shock proteins” has a pivotal role in controlling the normal immune response to infections. Scancell’s ImmunoBody technology has been licensed for use in non-cancer treatments.

Visit the company website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Nov 2005
cost: £868,000
valn at: 30/06/2018 £nil
equity held: 2.0%

+ Click for info

Insense Ltd - Unquoted

- Click to close

Insense Ltd - Unquoted


Insense has developed an innovative product range for the chronic wound care market – this is a growing market due to, inter alia, the increasing average age of populations and the growing incidence of diabetes. Technology developed by the company has been spun out into Archimed (qv) and Arecor (qv). Following these two spin-outs, Insense is concentrating on using its technology to develop dermatology products for both professional and consumer applications.

Click here to visit the company website

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Jul 2003
cost: £509,000
valn at: 30/06/2018 £121,000
equity held: 4.6%

+ Click for info

Microarray Ltd (formerly Archimed LLP) - Unquoted

- Click to close

Microarray Ltd (formerly Archimed LLP) - Unquoted


Archimed was a spin-out from Insense (qv) to commercialise wound dressing technology developed by Insense for the chronic wound care market – this is a growing market due to, inter alia, the increasing average age of populations and the growing incidence of diabetes.

In 2014, a restructuring resulted in the investment in Archimed LLP becoming a shareholding in Microarray Ltd, following the sale of Archimed LLP with its developed products – the rights to the principal product under development was excluded from the sale and transferred to Microarray.

Visit the company website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Jan 2011
cost: £132,000
valn at: 30/06/2018 £67,000
equity held: 1.8%

+ Click for info

Omega Diagnostics Group Plc - AIM Listed

- Click to close

Omega Diagnostics Group Plc - AIM Listed


Omega Diagnostics provides high quality In Vitro diagnostic products for use in hospitals, blood banks, clinics and laboratories in over 100 countries – its particular focus is on food allergy/intolerance tests.

Visit the company website here

Last Updated: 24/07/2018

Investment Information:
date of first inv: Sep 2007
cost: £328,000
valn at: 30/06/2018 £271,000
equity held: 1.8%

+ Click for info

OR Productivity Plc - Unquoted

- Click to close

OR Productivity Plc - Unquoted


Freehand 2010 acquired the business of Freehand Surgical Ltd following the latter being placed in administration in December 2010.

Freehand is positioning itself to become the leading supplier of low cost robotic laparoscope controllers for use by keyhole surgeons. Freehand is a successor product to EndoAssist (an instrument which was very large and expensive vs. Freehand being portable and inexpensive) which enabled keyhole surgeons to control the camera directly (via a unique control system guided by head movement) without the use of an assistant. Freehand, was launched in 2009 – the benefits are cost saving (vs. using an assistant), immediate performance of surgeon’s instructions and a steady picture, which lead to shorter operation times and better patient outcomes.

At the end of 2011, Freehand 2010 was acquired by OR Productivity plc (ORP) in exchange for ORP shares. ORP was founded by two people with very senior MedTech experience in order to commercialise products able to enhance the productivity of Minimally Invasive Medicine, which embraces keyhole surgery. The Freehand product is perceived as a platform product for other productivity enhancing products which are appearing for keyhole surgeons.

Visit the company website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Mar 2011
cost: £765,000
valn at: 30/06/2018 £664,000
equity held: 11.1%

+ Click for info

Scancell Holdings PLC - AIM Listed

- Click to close

Scancell Holdings PLC - AIM Listed


Scancell is a Nottingham-based company that is developing a pipeline of drugs to target various types of cancer. These products are derived from Scancell’s proprietary ImmunoBody technology. The first trial being undertaken is for a treatment for melanoma, with a Phase I trial scheduled having started in the UK during Q2 2010.

During 2006, the company sold its pipeline of antibodies to Peptech Ltd, an Australian biotechnology company, in a deal that had a total value of up to £4.85 million.

Dendreon is pursuing a similar scientific approach to Scancell but is taking a different approach to the way in which the treatment is provided. You can visit the Dendreon website by clicking here.

Visit the Scancell website here

 

Last Updated: 24/07/2018

Investment Information:
date of first inv: Dec 2003
cost: £801,000
valn at: 30/06/2018 £1,631,000
equity held: 3.42%